Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.78 |
| ▸ | FBP1 | P09467 | 4/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795102 | 0.88 | EGFR (1.00) | EGFRFBP1ERBB2ABL1SRC | |
| SCHEMBL6794722 | 0.88 | EGFR (1.00) | EGFRFBP1ERBB2KDM4EABL1 | |
| SCHEMBL6795090 | 0.86 | EGFR (0.65) | EGFRFBP1ERBB2KDM4EGAK | |
| SCHEMBL6794863 | 0.85 | EGFR (0.74) | EGFRFBP1ERBB2GAKABL1 | |
| SCHEMBL12648302 | 0.85 | EGFR (0.72) | EGFRFBP1ERBB2KDM4EGAK | |
| SCHEMBL6796326 | 0.83 | EGFR (0.71) | EGFRFBP1ERBB2GAKABL1 | |
| SCHEMBL24329477 | 0.78 | EGFR (1.00) | EGFRABL1SRC | |
| SCHEMBL9423 | 0.76 | EGFR (1.00) | EGFRFBP1ERBB2KDM4EGAK | |
| SCHEMBL30363011 | 0.76 | EGFR (1.00) | EGFRFBP1ERBB2KDM4EGAK | |
| SCHEMBL29444884 | 0.76 | EGFR (1.00) | EGFRFBP1ERBB2KDM4EGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835735-B2 | Anticancer, tyrosine kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-12-28 | — | — | US | disclosed |
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | KOREAN INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045537-A1 | 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same | EGFR, ERBB2, ERBB4 | EGFR 1/4885FBP1 2075/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.